Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1315-1319

  Inoue, Kenji ^a   Iwasa, Mayumi ^a   Wakakura, Masato ^a   Tomita, Goji ^b  

^a Nishikasai Inouye Eye Hospital   (Japan)

^b TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

BAK free travoprost; Event analysis; Intraocular pressure; Trend analysis; Visual field

Indexed keywords

BENZALKONIUM; EYE DROPS; TRAVOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; EVENING DOSAGE; EYE DISCHARGE; EYELID DISEASE; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PERIMETRY; UVEITIS; VISUAL FIELD DEFECT;

EID: 84865833340     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S33816     Document Type: Article

References (20)

1. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol. 1998;126(4):487-497.
2. Collaborative Normal-Tension Glaucoma Study-Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498-505.
3. Gusset AR. Benzalkonium chloride toxicity to the human cornea. Am J Ophthalmol. 1977;84(2):169-171.
4. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98-103.
5. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17(3):217-222.
6. McNaught AL, Crabb DP, Fitzke FW, Hitchings RA. Visual field progression: comparison of Humphrey Statpac 2 and pointwise linear regression analysis. Graefes Arch Clin Exp Ophthalmol. 1996;234(7):411-418.
7. Flammer J, Drance SM, Augustiny L, Funkhouser A. Quantification of glaucomatous visual field defects with automated perimetry. Invest Ophthalmol Vis Sci. 1985;26(2):176-181.
8. Macky TA. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study. J Ocul Pharmacol Ther. 2010;26(6):605-610.
9. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-484.
10. Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2003;20(3):149-163.
11. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure. Ophthalmology. 2002;109(5):998-1008.
12. Goldberg I, Cunha-Vaz J, Ratliff M, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10(5):414-422.
13. Parmaksiz S, Yüsel N, Karabas VL, Özkan B, Dermirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16(1):73-80.
14. Ang GS, Kersey JP, Shepstone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomized controlled trial. Br J Ophthalmol. 2008;92(8):1129-1133.
15. Suh MH, Park KH, Kim DH. Effect of travoprost on intraocular pressure during 12months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53(1):18-23.
16. Nomura Y, Nakakura S, Moriwaki M, Takahashi Y, Shiraki K. Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol. 2010;4:643-647.
17. Sawada A, Yamamoto T, Takatsuka N. Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2012;250(1):123-129.
18. Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21(1):60-64.
19. Inoue K, Wakakura M, Tomita G. Effects of levobunolol treatment in patients with normal-tension glaucoma for 5 years. Folia Japonica de Ophthalmologica Clinica. 2011;4(2):115-119.
20. Inoue K, Noguchi K, Wakakura M, Tomita G. Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma. Clin Ophthalmol. 2011;5:1211-1216.